(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While there are many available treatment options, to date, we have been unable to widely operationalize rationale treatment selection in this disease space. In many cases, oncologic outcomes are similar between treatment options. Both darolutamide and enzalutamide are next-generation androgen receptor inhibitors with demonstrated activity in men with CRPC. While both have demonstrated oncologic efficacy, the toxicity of these agents differs. In the Prostate, Testicular, Penile Poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, Dr. Emeline Colomba presented results of the ODENZA trial to assess whether differences in toxicity affect patient preference among those with early mCRPC.